Key terms
About OCGN/
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest OCGN/ news
No recent TipRanks articles are available for OCGN/
No recent press releases are available for OCGN/
OCGN/ Financials
Key terms
Ad Feedback
OCGN/ Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
OCGN/ Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
